$ZOM
Zomedica Corp.

2024 Q2 Form 10-K Financial Statement

#000155837024004517 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q4 2023
Revenue $6.131M $7.337M $25.19M
YoY Change 1.84% 19.17% 33.05%
Cost Of Revenue $1.769M $2.264M $7.868M
YoY Change -10.29% 21.52% 49.07%
Gross Profit $4.362M $5.073M $17.32M
YoY Change 7.76% 18.14% 26.85%
Gross Profit Margin 71.15% 69.14% 68.76%
Selling, General & Admin $11.90M $13.36M $43.17M
YoY Change 19.82% 54.43% 30.82%
% of Gross Profit 272.79% 263.41% 249.26%
Research & Development $1.506M $3.099M $5.744M
YoY Change 75.32% 298.84% 122.81%
% of Gross Profit 34.53% 61.09% 33.17%
Depreciation & Amortization $351.0K $1.870M $830.0K
YoY Change 3.24% 51.79% 94.84%
% of Gross Profit 8.05% 36.86% 4.79%
Operating Expenses $13.41M $16.46M $48.91M
YoY Change 24.24% 74.57% 37.48%
Operating Profit -$25.07M -$11.39M -$31.59M
YoY Change 271.8% 121.75% 44.1%
Interest Expense $992.0K $1.231M $175.0K
YoY Change 1500.0% -3.45% 17400.0%
% of Operating Profit
Other Income/Expense, Net $52.00K -$115.0K $2.080M
YoY Change -11600.0% -29814.29%
Pretax Income -$24.07M -$21.95M -$35.86M
YoY Change 352.01% 468.87% 85.03%
Income Tax -$143.0K $459.0K -$1.331M
% Of Pretax Income
Net Earnings -$23.93M -$22.41M -$34.53M
YoY Change 355.92% 697.65% 102.93%
Net Earnings / Revenue -390.33% -305.38% -137.1%
Basic Earnings Per Share -$0.02 -$0.04
Diluted Earnings Per Share -$0.02 -$0.02 -$0.04
COMMON SHARES
Basic Shares Outstanding 979.9M 979.9M 979.9M
Diluted Shares Outstanding 979.9M 979.9M

Balance Sheet

Concept 2024 Q2 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $79.51M $90.50M $90.50M
YoY Change -39.06% -21.37% -21.37%
Cash & Equivalents $7.939M $12.95M $12.95M
Short-Term Investments $71.57M $77.55M $77.55M
Other Short-Term Assets $2.100M $2.064M $2.064M
YoY Change -41.04% -45.67% -45.67%
Inventory $5.507M $5.123M $5.123M
Prepaid Expenses
Receivables $1.383M $1.197M $2.198M
Other Receivables $724.0K $1.001M $0.00
Total Short-Term Assets $89.22M $99.88M $99.88M
YoY Change -36.1% -19.12% -19.12%
LONG-TERM ASSETS
Property, Plant & Equipment $24.98M $10.35M $25.29M
YoY Change 242.6% 51.96% 175.95%
Goodwill $45.56M $61.58M
YoY Change -28.8% -3.75%
Intangibles $53.22M $55.36M
YoY Change 10.71% 32.45%
Long-Term Investments $3.482M $10.01M $10.01M
YoY Change -70.79% -75.42% -75.42%
Other Assets $1.185M $822.0K $1.072M
YoY Change 347.17% 210.19% 136.64%
Total Long-Term Assets $130.7M $153.3M $153.3M
YoY Change -3.33% -1.79% -1.79%
TOTAL ASSETS
Total Short-Term Assets $89.22M $99.88M $99.88M
Total Long-Term Assets $130.7M $153.3M $153.3M
Total Assets $219.9M $253.2M $253.2M
YoY Change -19.98% -9.45% -9.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.323M $7.668M $7.668M
YoY Change -62.19% 14.48% 14.48%
Accrued Expenses $4.370M $981.0K $981.0K
YoY Change 5805.41% 424.6% 424.6%
Deferred Revenue $271.0K $276.0K
YoY Change 6.27% 33.33%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.835M $9.032M $9.032M
YoY Change 8.67% 15.63% 15.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $736.0K $944.0K $3.010M
YoY Change -66.25% -49.87% 45.76%
Total Long-Term Liabilities $736.0K $944.0K $3.010M
YoY Change -66.25% -49.87% -4.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.835M $9.032M $9.032M
Total Long-Term Liabilities $736.0K $944.0K $3.010M
Total Liabilities $11.16M $13.18M $13.18M
YoY Change -27.03% 7.87% 7.87%
SHAREHOLDERS EQUITY
Retained Earnings -$204.0M -$170.9M
YoY Change 37.82% 25.31%
Common Stock $412.8M $410.9M
YoY Change 1.15% 1.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $208.7M $240.0M $240.0M
YoY Change
Total Liabilities & Shareholders Equity $219.9M $253.2M $253.2M
YoY Change -19.98% -9.45% -9.45%

Cashflow Statement

Concept 2024 Q2 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$23.93M -$22.41M -$34.53M
YoY Change 355.92% 697.65% 102.93%
Depreciation, Depletion And Amortization $351.0K $1.870M $830.0K
YoY Change 3.24% 51.79% 94.84%
Cash From Operating Activities -$6.719M -$5.015M -$15.98M
YoY Change 82.78% 110.45% 36.89%
INVESTING ACTIVITIES
Capital Expenditures $1.266M $2.065M $496.0K
YoY Change 1218.75% 161.39% -36.98%
Acquisitions $23.96M
YoY Change -1.42%
Other Investing Activities $5.038M -$1.764M $17.07M
YoY Change -78.49% -87.89% -111.15%
Cash From Investing Activities $3.772M -$3.829M $1.577M
YoY Change -83.83% -75.06% -101.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -6.719M -5.015M -15.98M
Cash From Investing Activities 3.772M -3.829M 1.577M
Cash From Financing Activities
Net Change In Cash -2.947M -8.844M -14.40M
YoY Change -115.0% -50.13% -91.41%
FREE CASH FLOW
Cash From Operating Activities -$6.719M -$5.015M -$15.98M
Capital Expenditures $1.266M $2.065M $496.0K
Free Cash Flow -$7.985M -$7.080M -$16.47M
YoY Change 111.69% 123.13% 32.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
979949668
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
979949668
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001684144
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38298
CY2023 dei Entity Registrant Name
EntityRegistrantName
ZOMEDICA CORP.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
Z4
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Phoenix Drive
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 125
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Ann Arbor
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48108
CY2023 dei City Area Code
CityAreaCode
734
CY2023 dei Local Phone Number
LocalPhoneNumber
369-2555
CY2023 dei Security12b Title
Security12bTitle
Common Shares
CY2023 dei Trading Symbol
TradingSymbol
ZOM
CY2023 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
192900000
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
979949668
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
248
CY2023 dei Auditor Name
AuditorName
GRANT THORNTON LLP
CY2023 dei Auditor Location
AuditorLocation
Southfield, Michigan
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12952000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27399000
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
77545000
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
87693000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1197000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
596000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5123000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2746000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2064000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3799000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1001000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1268000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
99882000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
123501000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
250000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
188000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10347000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6809000
CY2023Q4 zom Asset Construction In Progress Non Current
AssetConstructionInProgressNonCurrent
12481000
CY2022Q4 zom Asset Construction In Progress Non Current
AssetConstructionInProgressNonCurrent
692000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2466000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1665000
CY2023Q4 us-gaap Goodwill
Goodwill
61580000
CY2022Q4 us-gaap Goodwill
Goodwill
63979000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
55364000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
41799000
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
10005000
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
40712000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
822000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
265000
CY2023Q4 us-gaap Assets
Assets
253197000
CY2022Q4 us-gaap Assets
Assets
279610000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7668000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6698000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
65000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
187000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
916000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
641000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
276000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
207000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
107000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
78000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9032000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7811000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1814000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1097000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1138000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1245000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
252000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
182000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
944000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1883000
CY2023Q4 us-gaap Liabilities
Liabilities
13180000
CY2022Q4 us-gaap Liabilities
Liabilities
12218000
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
979949668
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
979949668
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
380973000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
380973000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
29929000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
23666000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-170933000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136404000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
48000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-843000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
240017000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
267392000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
253197000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279610000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25186000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18930000
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
7868000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
5462000
CY2023 us-gaap Gross Profit
GrossProfit
17318000
CY2022 us-gaap Gross Profit
GrossProfit
13468000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29029000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22934000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5744000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2578000
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14137000
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9879000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-31592000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-21923000
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
5458000
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
2701000
CY2023 us-gaap Interest Expense
InterestExpense
175000
CY2022 us-gaap Interest Expense
InterestExpense
1000
CY2023 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
24000
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2080000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
11683000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
28000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-152000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35860000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19381000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1331000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2366000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-34529000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-17015000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
936000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-869000
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-45000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
24000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33638000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17860000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
979949668
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
979949668
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.035
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.017
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
270888000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7891000
CY2022 zom Stock Issued Due To Exercise Of Warrants Amount
StockIssuedDueToExerciseOfWarrantsAmount
8000
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6465000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-17015000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-845000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
267392000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6263000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-34529000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
891000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
240017000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-34529000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-17015000
CY2023 us-gaap Depreciation
Depreciation
830000
CY2022 us-gaap Depreciation
Depreciation
426000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5468000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3616000
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
11683000
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
24000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
CY2023 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
2174000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
6263000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
7891000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
187000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
16000
CY2023 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
2209000
CY2022 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
900000
CY2023 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-1489000
CY2022 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-2540000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1059000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4008000
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1499000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1465000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
617000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
283000
CY2023 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-348000
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
334000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
384000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3454000
CY2023 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
-125000
CY2022 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
-53000
CY2023 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
30000
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-184000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
140000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
51000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-761000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-525000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15975000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11670000
CY2023 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-42775000
CY2022 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
127786000
CY2023 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
1750000
CY2022 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
1000000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
496000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
787000
CY2023 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
4150000
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
239000
CY2023 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
10843000
CY2022 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
1764000
CY2023 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
23959000
CY2022 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
24304000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1577000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-155880000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14398000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-167542000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-49000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-11000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27399000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194952000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12952000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27399000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
936000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-869000
CY2023 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
3494000
CY2022 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
1955000
CY2023 zom Transfer Of Inventory Into Property And Equipment
TransferOfInventoryIntoPropertyAndEquipment
696000
CY2022 zom Transfer Of Inventory Into Property And Equipment
TransferOfInventoryIntoPropertyAndEquipment
4331000
CY2023 us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
3317000
CY2022 us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
1588000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Estimates and Assumptions</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur, and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.</p>
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Comparative Figures </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">A portion of depreciation expense for the year ended December 31, 2023 has been stated as part of cost of revenue for </span><span style="font-style:normal;">$498</span><span style="font-style:normal;">. The consolidated statements of income and comprehensive loss for the year ended December 31, 2022 have been adjusted for </span><span style="font-style:normal;">$184</span><span style="font-style:normal;"> for depreciation that was included in selling, general, and administrative expense. This amount has been reclassified to cost of revenue to conform to the current year presentation. The change in presentation had no effect on the reported results of operations and does not affect previously reported cash flows from operating activities in the consolidated statements of cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">To better align with the way in which we measure and track our business, we have changed the categorization of products within our segmentation of revenue. A portion of the products in our Therapeutic Device segment were previously designated as instruments and trodes in our form 10K for the year ending December 31, 2022. These products have since been renamed to be capital and consumables to better align with our other platforms and to provide a more consistent baseline for comparison of the product lines within. Capital refers to the devices we sell within our PulseVet</span><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="font-style:normal;">, Revo Squared</span><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="font-style:normal;">, TRUVIEW</span><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">™</sup><span style="font-style:normal;"> and VetGuardian</span><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="font-style:normal;"> product lines. Consumables continues to include our TRUFORMA</span><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="font-style:normal;"> cartridges as it did last year and now includes our PulseVet trodes as well as our Assisi</span><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="font-style:normal;"> products. There have been no changes to the overall sales numbers for our Diagnostics and Therapeutic Device segments, only the product names making up the total.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">To provide further clarity on the way in which we present our operating expenses, we have broken up our SG&amp;A spend into distinct and separate General and Administrative and Selling and Marketing line items on the consolidated statements of income and comprehensive loss for the year ended December 31, 2023. The consolidated statements of income and comprehensive loss for the year ended December 31, 2022 have been adjusted to conform to the current year presentation of operating expenses. The change in presentation had no effect on the reported results of operations and does not affect previously reported cash flows from operating activities in the consolidated statements of cash flows.</span></p>
CY2023 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
498000
CY2023Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
95367000
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1308000
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
6345000
CY2023 zom Accounts Receivables Payment Term
AccountsReceivablesPaymentTerm
P30D
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
103000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
71000
CY2023Q4 zom Investment Securities Accumulated Accretion Or Amortization
InvestmentSecuritiesAccumulatedAccretionOrAmortization
1177000
CY2023Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
124000
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
96420000
CY2022Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
147797000
CY2022Q4 zom Investment Securities Accumulated Accretion Or Amortization
InvestmentSecuritiesAccumulatedAccretionOrAmortization
847000
CY2022Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
1061000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
147583000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
586000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
677000
CY2023Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
95367000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25186000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18930000
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
96420000
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
3827000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1685000
CY2023Q4 us-gaap Inventory Finished Goods And Work In Process
InventoryFinishedGoodsAndWorkInProcess
397000
CY2022Q4 us-gaap Inventory Finished Goods And Work In Process
InventoryFinishedGoodsAndWorkInProcess
182000
CY2023Q4 zom Inventory Purchase
InventoryPurchase
948000
CY2022Q4 zom Inventory Purchase
InventoryPurchase
919000
CY2023Q4 us-gaap Inventory Gross
InventoryGross
5172000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
2786000
CY2023Q4 us-gaap Inventory Adjustments
InventoryAdjustments
49000
CY2022Q4 us-gaap Inventory Adjustments
InventoryAdjustments
40000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5123000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2746000
CY2023Q4 us-gaap Deposit Assets
DepositAssets
919000
CY2022Q4 us-gaap Deposit Assets
DepositAssets
1886000
CY2023Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
259000
CY2022Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
114000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
436000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
614000
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
753000
CY2023Q4 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
700000
CY2022Q4 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
620000
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
2314000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
3987000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12392000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8086000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2045000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1277000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10347000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6809000
CY2023 us-gaap Depreciation
Depreciation
830000
CY2022 us-gaap Depreciation
Depreciation
426000
CY2021Q4 us-gaap Goodwill
Goodwill
43288000
CY2022 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
20857000
CY2022 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-166000
CY2022Q4 us-gaap Goodwill
Goodwill
63979000
CY2023 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
9796000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
12195000
CY2023Q4 us-gaap Goodwill
Goodwill
61580000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
65511000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
46479000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10147000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4680000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
55364000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
41799000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
6265000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
6100000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
5635000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
5408000
CY2023Q4 zom Finite Lived Intangible Assets Amortization Expense Year Five And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter
31393000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
54801000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5468000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3616000
CY2023Q4 zom Operating Lease Right Of Use Asset Aggregate Lease Commitments
OperatingLeaseRightOfUseAssetAggregateLeaseCommitments
4668000
CY2022Q4 zom Operating Lease Right Of Use Asset Aggregate Lease Commitments
OperatingLeaseRightOfUseAssetAggregateLeaseCommitments
2759000
CY2023Q4 zom Operating Lease Right Of Use Asset Impact Of Present Value
OperatingLeaseRightOfUseAssetImpactOfPresentValue
566000
CY2022Q4 zom Operating Lease Right Of Use Asset Impact Of Present Value
OperatingLeaseRightOfUseAssetImpactOfPresentValue
262000
CY2023Q4 zom Operating Lease Right Of Use Asset Cost
OperatingLeaseRightOfUseAssetCost
4102000
CY2022Q4 zom Operating Lease Right Of Use Asset Cost
OperatingLeaseRightOfUseAssetCost
2497000
CY2023Q4 zom Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
1825000
CY2022Q4 zom Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
946000
CY2023Q4 zom Operating Lease Rightofuse Asset Interest
OperatingLeaseRightofuseAssetInterest
189000
CY2022Q4 zom Operating Lease Rightofuse Asset Interest
OperatingLeaseRightofuseAssetInterest
114000
CY2023Q4 zom Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
1636000
CY2022Q4 zom Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
832000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2466000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1665000
CY2023 zom Operating Lease Liability Additions
OperatingLeaseLiabilityAdditions
4143000
CY2022 zom Operating Lease Liability Additions
OperatingLeaseLiabilityAdditions
2520000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
1602000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
896000
CY2023 zom Operating Lease Liability Interest
OperatingLeaseLiabilityInterest
189000
CY2022 zom Operating Lease Liability Interest
OperatingLeaseLiabilityInterest
114000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2730000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1738000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
916000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
641000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1814000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1097000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2730000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1738000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1069000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
632000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
603000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
569000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
234000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3107000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
377000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2730000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.064
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.045
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
1203000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
745000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
14655000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
84112443
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.3602
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
14655000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.2185
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4352500
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.3230
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1065000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.8744
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
93349943
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.3338
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
40508274
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.3577
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
50717724
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.4466
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
47292219
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.2692
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4300000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.6108
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
9597500
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.2601
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
84112443
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.3602
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
23850099
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.3698
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
93349943
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
40508274
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
52841669
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.96
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0047
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P9Y6M10D
CY2020Q4 us-gaap Share Price
SharePrice
0.21
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.22
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.17
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0109
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M8D
CY2021Q4 us-gaap Share Price
SharePrice
0.65
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.65
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.12
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0309
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2022Q4 us-gaap Share Price
SharePrice
0.26
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.27
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.08
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0396
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023Q4 us-gaap Share Price
SharePrice
0.21
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.22
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6263000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7891000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
32561418
CY2023 zom Sub Total Warrant Exercised Shares
SubTotalWarrantExercisedShares
360129250
CY2023 zom Sub Total Warrant Amount
SubTotalWarrantAmount
56933000
CY2023 zom Class Of Warrants Expired
ClassOfWarrantsExpired
351000
CY2023 zom Warrants Expired Amount
WarrantsExpiredAmount
55000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
158000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
174000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
158000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
174000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1547000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2306000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
58000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-234000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1489000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2540000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1331000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2366000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-36954000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-7435000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1094000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-11946000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35860000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19381000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.23
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.23
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35860000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19381000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8248000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4458000
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
674000
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
235000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
58000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-5000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
-1177000
CY2023 zom Effective Income Tax Rate Reconciliation Foreign Accrual Property Income
EffectiveIncomeTaxRateReconciliationForeignAccrualPropertyIncome
1505000
CY2022 zom Effective Income Tax Rate Reconciliation Foreign Accrual Property Income
EffectiveIncomeTaxRateReconciliationForeignAccrualPropertyIncome
9000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1183000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
241000
CY2023 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
-255000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3752000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2789000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1331000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2366000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
4236000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
4236000
CY2023Q4 zom Deferred Tax Assets Share Issuance Costs
DeferredTaxAssetsShareIssuanceCosts
1548000
CY2022Q4 zom Deferred Tax Assets Share Issuance Costs
DeferredTaxAssetsShareIssuanceCosts
2482000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
1050000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
478000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
9581000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
10668000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
8260000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
2885000
CY2023Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
165000
CY2022Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
208000
CY2023Q4 zom Deferred Tax Assets Operating Leases
DeferredTaxAssetsOperatingLeases
607000
CY2022Q4 zom Deferred Tax Assets Operating Leases
DeferredTaxAssetsOperatingLeases
83000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3246000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3067000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1737000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
476000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30430000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24583000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1878000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
491000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
558000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
80000
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
5702000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
6272000
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
11000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8149000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6843000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23419000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18985000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1138000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1245000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
265000
CY2023Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
9347000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-17015000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
979949668
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
979949668
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.035
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.017
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25186000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18930000
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
7868000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
5462000
CY2023 us-gaap Gross Profit
GrossProfit
17318000
CY2022 us-gaap Gross Profit
GrossProfit
13468000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-34529000

Files In Submission

Name View Source Status
0001558370-24-004517-index-headers.html Edgar Link pending
0001558370-24-004517-index.html Edgar Link pending
0001558370-24-004517.txt Edgar Link pending
0001558370-24-004517-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zom-20231231.xsd Edgar Link pending
zom-20231231x10k.htm Edgar Link pending
zom-20231231xex10d11.htm Edgar Link pending
zom-20231231xex10d11001.jpg Edgar Link pending
zom-20231231xex10d11002.jpg Edgar Link pending
zom-20231231xex10d11003.jpg Edgar Link pending
zom-20231231xex10d11004.jpg Edgar Link pending
zom-20231231xex10d11005.jpg Edgar Link pending
zom-20231231xex10d11006.jpg Edgar Link pending
zom-20231231xex10d12.htm Edgar Link pending
zom-20231231xex10d19.htm Edgar Link pending
zom-20231231xex10d19001.jpg Edgar Link pending
zom-20231231xex10d19002.jpg Edgar Link pending
zom-20231231xex10d20.htm Edgar Link pending
zom-20231231xex10d20001.jpg Edgar Link pending
zom-20231231xex10d20002.jpg Edgar Link pending
zom-20231231xex10d20003.jpg Edgar Link pending
zom-20231231xex10d20004.jpg Edgar Link pending
zom-20231231xex10d20005.jpg Edgar Link pending
zom-20231231xex21d1.htm Edgar Link pending
zom-20231231xex23d2.htm Edgar Link pending
zom-20231231xex31d1.htm Edgar Link pending
zom-20231231xex31d2.htm Edgar Link pending
zom-20231231xex32d1.htm Edgar Link pending
zom-20231231xex97d1.htm Edgar Link pending
zom-20231231_cal.xml Edgar Link unprocessable
zom-20231231_def.xml Edgar Link unprocessable
zom-20231231_lab.xml Edgar Link unprocessable
zom-20231231_pre.xml Edgar Link unprocessable
zom-20231231x10k_htm.xml Edgar Link completed